Moderna says COVID shot strongly responded to Pirola variant
Maddie Meyer/Getty Images News

Moderna, Inc. (NASDAQ:MRNA) announced Wednesday that its latest COVID vaccine led to a robust immune response in humans against the highly mutated Omicron variant BA.2.86, also known as Pirola.
Moderna's (MRNA) messenger-RNA-based vaccine adjusted for Omicron XBB.1.5 is currently under FDA review to clear it in time for an immunization drive in the fall.

Citing data from laboratory assays, the biotech said that the updated shot demonstrated an 8.7-fold increase in neutralizing antibodies against Pirola.
Data on the vaccine's effectiveness against Pirola have been shared with regulators and will be submitted for peer review publication, Moderna (MRNA) added.
The WHO has classified BA.2.86 as a "variant under monitoring" because of its large number of mutations. 
In August, the CDC warned that BA.2.86 could be more capable of causing infections in previously vaccinated individuals or those who had COVID-19 before.



More on Moderna

Seeking Alphaâs Quant Rating on Moderna
Historical earnings data for Moderna
Financial information for Moderna
Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases
Moderna: Buy Before The Fall Covid-19 Wave
Moderna Falling As Vaccine Hesitancy Rises

Moderna, Inc. (MRNA) Q2 2023 Earnings Call Transcript
New COVID variant can cause infection in those previously vaccinated - CDC